The Immuno-Oncology Assays Market: Navigating Challenges and Future Prospects

According to the latest study conducted by Research Report Insights (RRI) the global market for precision medicine is anticipate grow manifold, reflecting a robust CAGR of over 14% during 2016 to 2024.

Rapid augmentation of the medicine industry across the globe will certainly benefit the global market for precision medicine. In addition, factors such as growing infrastructural development, higher investments, streamlined drug approval systems along with companion diagnostics are expected to favor the overall market growth during the assessment period. Cost-effective DNA profiling and increasing prevalence of carcinogenic diseases worldwide are additional factors that are projected to propel the market growth. Moreover, apt storage of genome data is of great significance to the global market for precision medicine as demand for data medicare is on the rise. However, acute data storage capacity, data privacy breach and discrepancies in funding systems and hefty price tag of personalized drugs may deter the market growth in the near future.

Report For Sample with Table of Contents@ https://www.researchreportinsights.com/report/sample/110114684/Precision-Medicine-Market

The global market for precision medicine has been categorized into various parent segments that are further segmented into smaller sub-divisions.

On the basis of technology, next-gen sequencing, bioinformatics and drug discovery technology are expected to be the technologies highlighting the expanding the market width in forthcoming years. Based on applications, the oncology segment is expected to witness an overwhelming growth and is estimated to reach US$ 69 Billion over 2024, reflecting a staggering 13.5% CAGR.  This is primarily owing to increasing prevalence of tumor-related disease amongst the global geriatric population. On the other hand, increasing cases of arthritis will favor the growth of immunology segment, which is expected to surpass US$ 34 Million in revenues by 2024 end.

The popularity of precision medicine has grown significantly across various parts of the world, hence on the basis of region, the markets for precision medicine in Asia Pacific, North America, Europe, Latin America, and the Middle East and Africa (MEA) is set to achieve new figures of growth over the next eight years. Precisely, the market in North America is expected to present new lucrative opportunities, occupying over 35% share of the market during the forecast period. In addition, the region is estimated to surpass a market valuation of over US$ 60 Million by the end of 2024.

Request For Report Discount@ https://www.researchreportinsights.com/report/discount/110114684/Precision-Medicine-Market

The US and Canada will be the heavyweights of the global market owing to the existence of well-established medical industries in both the countries. In Europe, the market is expected to witness a steady growth and will increase its revenues charts close to US$ 40 Million, riding on a healthy CAGR of over 13% during the assessment period. This is largely due to the increasing demand for precision medicines in countries such as France, UK, Italy and Germany. The Asia Pacific region is another region which is considered to be full of business potentials. The region is projected to increase at over 14% CAGR to reach approximately US$ 35 Million by 2024 end. The market in APAC will be heavily dominated by Japan, while, India and China will compete for the second spot. Likewise, the in Latin America the market is expected to surge at a pace in terms of revenue over 2024. However, MEA will witness a sluggish growth of the market which is attributed to the lack of initiatives for conductive extensive research and development activities.

Vendor News

Key players operating in the global market for precision medicine include Eli Lilly And Company, Novartis AG, AstraZeneca and Laboratory Corporation of America Holdings. Most of the companies are implementing market strategies involving mergers, tie-ups and acquisitions. Increasing collaboration between healthcare and IT is expected to deliver fruitful gains to the market, expanding the overall business canvas for the stakeholders in the upcoming years.

Report Analysis@ https://www.researchreportinsights.com/report/rd/110114684/Precision-Medicine-Market

1 March 2019, The global Liquid Biopsy Market is projected to witness substantial growth over the forecast period (from 2017 to 2025) owing to advancement in liquid biopsy tests and extensive R by major companies.

Moreover, highly invasive nature and frequent complications associated with tissue biopsy and advancements in Next-Generation Sequencing (NGS) is anticipated to fuel demand for liquid biopsy in coming years.Liquid biopsies make use of bio fluid samples, such as blood, urine sample, tissue fluids, and saliva.

The technology is widely used in molecular health monitoring, therapy selection for Metastatic Breast Cancer (MBS), and other related cancers.

MBS is likely to emerge as a leading application over the forecast period as a result of growing cases of metastatic cancer across the world.

PCR-based sequencing is used for analysis of mutations in disease-specific genes, whereas NGS testing is used for simultaneous analysis of multiple diseases.

Rising awareness about benefits of multiple-gene analysis and NGS is projected to have a positive impact on the market growth over the next few years.The market can be segmented on the basis of geography as North America, Latin America, Asia Pacific, Europe, and MEA.

This report aims to provide detailed insights into the NGS-based RNA-sequencing market.

It provides valuable information on the type, procedure, application, and region in the market.

Expected Revenue Growth: The NGS-based RNA-sequencing industry size is projected to reach USD 4.2 billion by 2024 from USD 1.7 billion in 2019, at a CAGR of 20.0% during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=102977816 Key Factors Driving Market Growth: Market growth is driven mainly by the advantages of RNA-seq over conventional technologies; an increasing number of RNA-seq grants; rising number of research activities involving RNA-seq; and rapid growth in precision medicine market.

The expression profiling analysis segment accounted for the largest share of the NGS-based RNA-sequencing industry, by application, in 2018 Based on application, the NGS-Based RNA-Sequencing Market is segmented into expression profiling analysis, small RNA sequencing, De Novo transcriptome assembly, and variant calling & transcriptome epigenetics.

Nanopore sequencing technology registers the highest growth rate in the market as it is the only sequencing technology with direct RNA sequencing capabilities and facilitates sequencing of full-length RNA strands and modified RNA nucleotides using a simple library prep, without the need of conversion to double-stranded DNA.

The global Precision Medicine Market research report, published by Value Market Research, is designed to offer various market framework such as market size, portion, trends, growth path, value and factors that impact the current market dynamics over the forecast period 2020-2027.

Most importantly, this report also provides the latest significant strategies adopted by major players along with their market share.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.

The major players in the precision medicine market include Roche Holding AG, Illumina Inc., Thermo Fisher Scientific Inc., QIAGEN, Quest Diagnostics, Laboratory Corporation of America Holdings, Novartis AG, AstraZeneca, Bristol-Myers Squibb, Eli Lilly & Company and others..

This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Precision Medicine Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/precision-medicine-market/download-sampleMarket DynamicsThe market is mainly driven by increasing approval of the drug and its companion diagnostic assay, cost-effective profiling of DNA, increasing incidence of cancer, and the rise of data-driven healthcare.

In addition, the rising use of “multi-omics” in research, along with the penetration of high-throughput sequencing platforms, is also surging up the precision medicine scenario.

The number of targeted molecules in the pipeline for a specific application has been exponentially growing, specifically in oncology has created a new opportunity over the forecast period.